Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jun 9, 2011

Premium

Alnylam Pharmaceuticals this week announced that CSO Kenneth Koblan is leaving the company.

According to Alnylam CEO John Maraganore, Koblan has “decided to return to big pharma … for personal reasons.”

Koblan held various positions at Merck Research Laboratories before joining Alnylam in November last year. Before that, the company had been without a CSO since John Schmidt left in August 2009.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.